Autoimmune Disease Diagnostics Market Size By Disease Type (Systemic Autoimmune Disease {Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Psoriasis, Multiple Sclerosis}, Localized Autoimmune Disease {Inflammatory Bowel Disease, Type 1 Diabetes, T

Autoimmune Disease Diagnostics Market Size By Disease Type (Systemic Autoimmune Disease {Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Psoriasis, Multiple Sclerosis}, Localized Autoimmune Disease {Inflammatory Bowel Disease, Type 1 Diabetes, Thyroid}), By Test Type (Antinuclear Antibody Tests, Autoantibody Tests, C-reactive Protein (CRP), Complete Blood Count (CBC), Urinalysis), By End-use (Hospitals, Diagnostics Centers), Industry Analysis Report, Regional Outlook, Covid-19 Impact Analysis, Application Potential, Competitive Market Share & Forecast, 2022 - 2030

The autoimmune disease diagnostics market is projected to grow massively by 2030 owing to escalating prevalence of autoimmune diseases around the world. In addition, technological advancements in the field of diagnostics and supportive government initiatives for R&D activities are speculated to impel market growth over the forecast period.

Recently, a December 2021 study published in Cells analyzed the dysregulation of the immune system caused by the COVID-19 infection, which could lead to the development of autoimmune phenomena. The research findings indicated that the coronavirus infection could precipitate systemic and rheumatic autoimmune diseases, establishing a link between the illness and new onset-rheumatic diseases to promote early diagnosis and timely therapeutic management.

Thus, the burgeoning need for diagnosing autoimmune diseases has fueled autoimmune disease diagnostics market growth considerably. Moreover, rapid advancements in autoimmune disease diagnostic systems have also stimulated business growth in the past few years.

Major companies have been focusing on strategic partnerships, mergers, collaborations, and product innovation to maintain a strong presence in the market, fostering the competitive outlook of the industry. For instance, in March 2021, Bio-Rad Laboratories, a medical device company, extended its agreement with diagnostics behemoth Roche by offering its InteliQ product range. This deal aimed to fortify the partnership between the two firms.

The autoimmune disease diagnostics market has been bifurcated in terms of end-use, test type, disease type, and region.

By disease type, the autoimmune disease diagnostics industry has been split into localized autoimmune disease and systemic autoimmune disease. The systemic autoimmune disease segment was valued at more than $327 million in 2021 attributed to the growing influence of rheumatoid arthritis, systemic lupus erythematosus (SLE), psoriasis, and so on, which has increased the need for diagnosis of these conditions.

The autoimmune disease diagnostics market has been categorized on the basis of test type into urinalysis, antinuclear antibody tests, complete blood count (CBC), autoantibody tests, c-reactive protein (CRP), and others. In 2021, the antinuclear antibody tests segment accounted for a revenue share of around 43% as a result of rising incidences of chronic ailments and diseases that target the immune systems such as type 1 diabetes, myasthenia gravis, and others.

With regards to end-use, the autoimmune disease diagnostics industry has been divided into diagnostics centers, hospitals, and others. The hospitals segment attained a valuation of over $591 million in 2021 on account of viable medical policies and surging availability of modern autoimmune diagnostics technologies that promote patient satisfaction and convenience.

In the regional landscape, the North America autoimmune disease diagnostics market is poised to grow at a CAGR of above 5.9% over the review period on account of the mounting prevalence of autoimmune diseases and growing awareness about diagnostic procedures in the region.